Evidence map›Paper›PMID 39819645›Full record

ArticleeLife2025

Altering the redox status of

Vandana Singh, Scot P Ouellette

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Vandana SinghDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, United States.ORCID https://orcid.org/0000-0001-5368-6200
Scot P OuelletteDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, United States.ORCID https://orcid.org/0000-0002-3721-6839

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHANG, YING · 2016 to 2025
$42.8M
Functional Analysis of the Clp Protease Systems in Chlamydial Growth and DifferentiationR01AI170688 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Derek James Fisher, Scot P Ouellette · 2022 to 2026
$2.1M
Characterizing the Redoxome of Chlamydia and Its Host CellR21AI178150 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUELLETTE, SCOT P · 2023 to 2024
$432k
NCI NIH HHS P30 CA036727NIAID NIH HHS R01 AI170688NIAID NIH HHS R21 AI178150NIGMS NIH HHS P20 GM103427NIGMS NIH HHS U54 GM115458NIH HHS R01AI170688NIH HHS R21AI178150
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chlamydia trachomatisBacterial ProteinsGene Expression Regulation, BacterialGene Knockdown TechniquesHumansOxidation-ReductionPeroxiredoxinsReactive Oxygen SpeciesBacterial ProteinsPeroxiredoxinsReactive Oxygen SpeciesAhpCChlamydiaCRISPRidevelopmental cycledifferentiationinfectious diseasemicrobiologyredox

Identifiers

PMID39819645
PMCPMC11741522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.